This clinical-stage monoclonal antibody, Xentuzumab – formerly known as BI 836845 – represents a promising effort by Astellas Inc. targeting Programmed cell death protein 1. Its journey initially focused on solid https://albertahrj309819.blog5.net/94421655/xentuzumab-a-deep-examination-into-bi-836845-and-its-evolution